University of California San Francisco
Give to UCSFUCSF researchers are part of a $200 million global consortium to develop new diagnostics, therapeutics, containment and control strategies to reduce the suffering from tuberculosis (TB) around the world.
San Francisco’s pandemic policy of offering hotel rooms, meals, and medical services to unhoused populations saw the unintended benefit of dramatically lowering the use of emergency medical services.
Overcrowding, antiquated buildings, rapidly changing conditions and the need for complex coordination helped drive a dramatic COVID-19 surge in California’s prisons, according to a new report from UCSF and UC Berkeley.
Parents of children under the age of five-years-old now have the option to vaccinate their infants and young children against COVID-19. Our expert looks at potential vaccine side effects, risks of COVID-19, access and vaccine effectiveness in children.
For the seventh consecutive year, UCSF is co-sponsoring the Precision Medicine World Conference (PMWC) from June 28-30, 2022 to share the latest in this rapidly evolving space.
Seth Blumberg, MD, PhD, an assistant professor of medicine, is clinical specialist in infectious disease, including Monkeypox. He offers insight in the recent outbreak in a Q&A.
A significant proportion of bacterial sexually transmitted infections – gonorrhea, chlamydia, or syphilis – were prevented with a dose of doxycycline after unprotected sex, according to preliminary results of a clinical trial.
In a new study of long COVID, UCSF researchers identified biomarkers present at elevated levels that may persist for many months in the blood of study participants who had long COVID with neuropsychiatric symptoms.
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
Scientists at UCSF QBI and the QBI Coronavirus Research Group (QCRG) have been awarded $67.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to support its mission of pandemic preparedness.
An antiviral drug approved for high-risk COVID patients may also benefit those with long COVID, according to the findings of a small case series that need to be confirmed with future rigorous studies.